John Celebi has over 20 years of experience building innovative entrepreneurial biotechnology companies.  Previously, Mr. Celebi served as the Chief Operating Officer of X4 Pharmaceuticals where he established and oversaw the company’s oncology business strategy.  He also served as Chief Business Officer of Igenica Biotherapeutics, Inc., an immunotherapy company formed by The Column Group, 5AM Ventures, Orbimed and Third Rock Ventures, where he established key academic and industry relationships, including with MedImmune.  He has extensive transactional and alliance management experience. Previously, he served as Vice President of Business Development, New Product Planning and Alliance Management at ArQule, Inc., where he played a central role in the formation of alliances with Roche, Daiichi-Sankyo, and Kyowa Hakko Kirin.  Mr. Celebi was one of the early employees at Tularik, Inc., where he conducted drug discovery and basic research for an anti-viral drug program. Mr. Celebi received an M.B.A. from Carnegie Mellon University and a B.S. in Biophysics from the University of California, San Diego.

Pauline Callinan has over a dozen years of experience forming partnerships between biotechnology companies, sources of venture capital and academic groups. Prior to joining Sensei, Dr. Callinan served in MedImmune’s Partnering and Strategy Group within the oncology therapeutic area, where she engaged in business development activities covering licensing of innovative assets, technologies and strategic partnerships. Prior to MedImmune, Dr. Callinan held various positions at Johns Hopkins Technology Transfer, most recently as Portfolio Director, Life Sciences, where she managed the Life Sciences Intellectual Property portfolio with a team of Technology Transfer Associates.  Dr. Callinan completed a post-doc at the Johns Hopkins School of Medicine where she studied the epigenetics of human disease.  She has published a book chapter, review articles and first authored publications in peer reviewed journals. Dr. Callinan holds a PhD degree in Biochemistry from the Louisiana State University, and a BSc Human Biology (with honors) from Loughborough University, U.K.

Ildiko Csiki has recently joined Sensei in August 2018.  She has both academic and industry experience in immune-oncology.  Dr. Csiki comes to Sensei from Inovio Pharmaceuticals where she had been Vice President Immuno-Oncology Clinical Development since 2016.  She also served for two years at Merck as Immuno-Oncology Clinical Lead and Senior Director of Clinical Research for Keytruda.  She was global lead for a large phase III gastric pivotal study.  Prior to that, Dr. Csiki was at GlaxoSmithKline in a blended role with medical monitor responsibilities on phase I, II, and III oncology clinical trials.  Dr. Csiki received both her BA and BS degrees from the University of Arkansas and her MD/PhD degrees in the medical scientist program at Vanderbilt University.  She completed sub-specialty training and residencies at Vanderbilt in Internal Medicine and Radiation Oncology.  She then served for two years as Assistant Professor of Radiation Oncology at the University of Pennsylvania.  Currently, Dr. Csiki is also pursuing a degree in general management from the Wharton Business School with a focus on Executive Coaching/Leadership and Strategic Innovation.

Alice Drumheller has over twenty years’ experience in the clinical operations area with the focus on executing clinical trials. Prior to joining the Sensei Bio, Alice was Senior Director of Clinical Operations at MacroGenics where she executed the company’s clinical strategy. Previous to MacroGenics, Alice was part of the team at Amgen/Micomet where she contributed to the approval of BLINCYTO®. Alice has held positions of increasing responsibility at large pharmaceutical companies, start-up companies and clinical research organizations, including Nabi Biopharmaceuticals, Bristol-Myers Squibb, Kendle (now Syneos), British Biotech and Henri Beaufour Institute (a subsidiary of Ipsen). Alice holds a BS in Public and Community Health from Southern Connecticut State University in New Haven, CT.

Steven Fuller has over 30 years of experience in the pharmaceutical and biotechnology industries working on a range of therapeutic and diagnostic products. Prior to joining Sensei, Dr. Fuller served as Vice President, Product and Process Development at Nabi Biopharmaceuticals, Inc. While at Nabi, he held positions of increasing responsibility in the development, GMP manufacture, quality control, quality assurance and clinical testing of vaccine and immune globulin products for infectious disease and drugs of addiction. Dr. Fuller was an integral part of a team that filed two biologics license applications for immunotherapeutic products and also filed numerous Investigation New Drug (IND) applications for vaccine products. At ADI Diagnostics, Inc., Toronto, Ontario, Dr. Fuller was Director of Operations for ADI’s diagnostics development and manufacturing of tests for cancer and infectious disease.  He is author of numerous peer-reviewed publications and multiple patents. Dr. Fuller received his B.S. degree in Biology from Wheaton College and his Ph.D. in genetics from Michigan State University.

Edward van der Horst is a molecular pharmacologist with a strong focus on antibody drug development across diverse target classes in oncology.  He has 18 years of research and development experience from Zenith Epigenetics Ltd, Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo).  Edward’s contributions and discoveries have led to the clinical evaluation of several novel drug candidates at Igenica Biotherapeutics and OncoMed Pharmaceuticals, as well as to the first clinical stage anti-HER3 antibody at U3 Pharma GmbH.  Edward earned his Ph.D. in biochemistry from the Max-Planck Institute of Biochemistry and conducted his master’s thesis at Max-Planck Institute of Neurobiology. He received his postdoctoral training at Tularik, Inc.  He graduated with a master’s degree of chemistry from the Ludwig Maximilian University of Munich.

Dr. Broder is the former Director of the National Cancer Institute (NCI), the largest and most important Agency for cancer research, where he was appointed by President Ronald Reagan in 1989.  While at the NCI, he oversaw the development of numerous anti-cancer therapeutic agents, helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer and inaugurated the highly successful SPORE Program.  Most recently, he served as Senior Vice President and Health Sector Head at Intrexon Corporation.  Dr. Broder spent his entire career in translational medicine and his laboratory interests have included antiretroviral therapy, the relationship between immunodeficiency disorders and cancer, the human genome, and the proteomics of cancer cells. In the mid-1980s, in response to the AIDS pandemic, he focused his attention on HIV-1/AIDS. His laboratory played a major role in developing the first 3 agents approved by FDA specifically to treat the AIDS virus, Retrovir® (AZT), Videx® (ddI), and HIVID® (ddC).  After serving as the Director of the NCI from 1989-1995, Dr. Broder served as Senior Vice President, Research and Development and Chief Scientific Officer at IVAX Corporation.  He then joined the Celera Corporation, as the Executive Vice President for Medical Affairs and Chief Medical Officer, and helped advance the human genome project, the elucidation of the 3 billion letters of code that make up human DNA. He has received numerous scientific awards related to his research in cancer and AIDS. He was elected to the Institute of Medicine of the National Academy of Sciences in 1993.

John Celebi has over 20 years of experience building innovative entrepreneurial biotechnology companies.  Previously, Mr. Celebi served as the Chief Operating Officer of X4 Pharmaceuticals where he established and oversaw the company’s oncology business strategy.  He also served as Chief Business Officer of Igenica Biotherapeutics, Inc., an immunotherapy company formed by The Column Group, 5AM Ventures, Orbimed and Third Rock Ventures, where he established key academic and industry relationships, including with MedImmune.  He has extensive transactional and alliance management experience. Previously, he served as Vice President of Business Development, New Product Planning and Alliance Management at ArQule, Inc., where he played a central role in the formation of alliances with Roche, Daiichi-Sankyo, and Kyowa Hakko Kirin.  Mr. Celebi was one of the early employees at Tularik, Inc., where he conducted drug discovery and basic research for an anti-viral drug program. Mr. Celebi received an M.B.A. from Carnegie Mellon University and a B.S. in Biophysics from the University of California, San Diego.

Mark Lee Ford leads business turnarounds of companies in industries such as financial services and consumer products. Based in Tokyo and Hong Kong, he also educates young entrepreneurs in the region by serving as a business school professor. Dr. Ford’s scientific interests include fluid mechanics and oncology. He received his BSc degree in Astrophysics from Trinity College, University of Toronto, MS and Ph.D. degrees in Aerospace Engineering from Boston University, and MBA degree from Duke University.

Hossein Ghanbari is a co-founder of Sensei Biotherapeutics and currently serves as its Board Chair.  He served as Chairman, CEO and CSO of the company until February 2018 during which he led the company into clinical studies with SNS-301 and was instrumental in raising significant financing for the company.  Dr. Ghanbari began his career in the pharmaceutical industry at Abbott Laboratories in Chicago, where he developed several pharmaceuticals and the first ever commercialized diagnostic test for Alzheimer’s Disease (AD).  He was part of the New Drug Application (NDA) team for Leupron, the successful prostate cancer drug, as well as for Survanta, the current drug of choice for preventing and treating respiratory distress syndrome in premature infants.  He directed the Analytical sections of the Investigational New Drug (IND) application for an antibody-based antiviral drug and was a member of Abbott’s Technical Advisory Board.  Dr. Ghanbari was inducted into the prestigious honorary organization, the Volwiler Society, established by Abbott to recognize the company’s most distinguished and accomplished scientists.  After nearly a decade with Abbott, Dr. Ghanbari left to form Molecular Geriatrics Corporation, (a biopharma company focused on developing drugs for neurodegenerative diseases) and served as its Senior Vice-President for R&D.  Subsequently, Dr. Ghanbari was instrumental in establishing Nymox Pharmaceutical Corporation (NASDAQ: NYMX), and served as Senior Vice-President for R&D and Strategic Planning as well as a Director on its board.  While with Nymox, he developed the first commercially available cerebral spinal fluid- and urine-based diagnostics tests for Alzheimer’s Disease (AD) and identified opportunities for complementary technologies that Nymox in-licensed, which together established the company’s international presence as a leader in AD diagnostics and therapeutics.  Prior to entering private industry, Dr. Ghanbari held professorships at Pennsylvania State University, University of Florida, and Arya-Mehr University of Technology (now Sharif University).  He was also on the academic staff of The George Washington University School of Medicine and Health Sciences as an Adjunct Professor.  He currently serves as a Board member of the Gastric Cancer Foundation.  Dr. Ghanbari received his Bachelor of Sciences degree, with distinction, from the American University in Beirut, and his master’s and doctorate degrees in Biochemistry from Pennsylvania State University.  He has authored over 70 peer reviewed publications, and is an inventor on nearly 100 patents and patent applications worldwide.

Mehdi Hatamian received his B.S.  degree in Electrical Engineering from Sharif University of Technology in 1977, and M.S. and Ph.D. degrees in Electrical Engineering from the University of Michigan in Ann Arbor, in 1978 and 1982 respectively.  Most recently, Dr. Hatamian was Chief Scientist of Central Engineering and Fellow at Broadcom Limited, and Senior VP Engineering at Broadcom Corporation. Previously, Dr. Hatamian worked for NASA’s Space Shuttle program, developing hardware and software designs to support in-flight biomedical experiments. He was a member of the Visual Communications Research and the VLSI Systems Research departments of Bell Laboratories, where he was named Distinguished Member of the Technical Staff. He also served as Vice President of Technology at Silicon Design Experts (SDE), Inc., a company he co-founded. SDE was acquired by Level One Corp. which was later acquired by Intel Corp.  He has published 50 papers and holds 94 issued patents with several patents pending.  Dr. Hatamian has been inducted in the National Academy of Engineering for his contributions to the development of integrated circuits for video, communications, and digital signal processing. He is a Fellow member of the Institute of Electrical and Electronics Engineers (IEEE). Dr. Hatamian received the “#1 Patent Holder” award from Broadcom Corp. and the Broadcom Fellow award. He received the University of Michigan’s ECE Division Alumni Merit Award for 2008. He served on the Engineering Advisory Council of the University of Michigan. He has participated in numerous national and international conferences and other professional activities in his field as keynote speaker, organizer, session chair, panelist, invited lecturer, and moderator. In addition to Sensei Bio, Dr. Hatamian has served on the board of directors of PharmacoKinesis, Inc.

Mr. Holmen has over 25 years’ experience working in and advising technology, healthcare and financial services companies.  He has engaged at every phase of corporate development, from formation to financing to operations to exiting, and has served in diverse roles from electrical engineer (Hughes Aircraft) to an associate at major law firms (Latham &Watkins, Morrison & Foerster) to general counsel for a series of technology and financial services companies to co-founder and managing director for a family of venture funds (Miramar Venture Partners).

Currently, Mr. Holmen provides legal services to investors through his boutique law firm Investor Counsel, focused on the venture capital and private equity markets.  His work encompasses fund formation, financing and operations, structuring and negotiating investments, mergers and acquisition, and purchaser representation.  In addition, he continues to serve as a Managing Director for the legacy (fully invested) Miramar Venture Partners funds.  Mr. Holmen also has served as an adjunct professor, teaching “Venture Capital Law” at the UC, Irvine Law School and “Investing in New Ventures” at USC’s Marshall School of Business, in addition to writing about venture and M&A matters.  He received his B.S. in Electrical Engineering from Stanford University and his J.D. from UC Berkeley School of Law (Boalt Hall).

Tom Ricks has been a member of the Board of Directors since 2015. Mr. Ricks is the former Chief Investment Officer of H&S Ventures LLC, a private investment firm. Prior to taking this position with H&S Ventures, he was Chief Executive Officer of The University of Texas Investment Management Company. Mr. Ricks also served as Vice Chancellor for Asset Management for The University of Texas System and as Executive Director of Finance and Private Investments. He has been a director of Newfield Exploration Company (NYSE:NFX) since 1992 and is Chairman of its Audit Committee. He is a former director of BDM International, DTM Corporation, LifeCell Corporation and Argus Pharmaceuticals. Mr. Ricks also previously served on the Investment Committee of the University of California Foundation, Irvine and previously served on the board of the Ocean Institute.   Mr. Ricks holds a B.A. in Economics from Trinity College, an M.B.A. from the University of Chicago.

Alain Algazi, M.D., is an oncologist and Associate Professor at The University of California San Francisco Helen Diller Family Comprehensive Cancer Center. Dr. Algazi conducts clinical trials on personalized medical therapies for patients with head and neck and high-risk skin cancers, in addition to serving as the leader of the head and neck medical oncology research program at UCSF. Dr. Algazi has served as the national study chair for several pivotal trials in oncology and is a member of the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer, and the American Association for Cancer Research. He also served previously as a member of The National Comprehensive Cancer Network Melanoma Panel.

Saar Gill, M.D., Ph.D., is an Assistant Professor of Medicine at the University of Pennsylvania, where his clinical practice is bone marrow transplantation. His laboratory studies novel approaches to produce effective and safe CAR T cells for the treatment of hematologic malignancies and CAR macrophages for the treatment of solid cancers. Dr. Gill is a scientific committee member at the American Society of Gene & Cell Therapy (where he is a recent past Chair of the Cancer Gene and Cell Therapy committee) and at the American Society of Hematology, and he was recently elected to the American Society of Clinical Investigation.

Sara Pai, M.D., Ph.D., is an Associate Professor of Surgery at Harvard Medical School and an Associate Surgeon and Director of Translational Research in Head and Neck Cancer at Massachusetts General Hospital. She leads several immunotherapy trials in head and neck cancer patients.  Pai’s research interests focus on understanding mechanisms of immune evasion utilized by the human papillomavirus (HPV) and evaluates novel ways to reactive the host immune response against the virus as it relates to cancer cells. Dr. Pai is recognized both nationally and internationally as an expert in HPV-associated head and neck cancers and cancer immunotherapy, in addition she has a research laboratory that is supported by the National Institutes of Health (NIH) as well as industry.

Robert Pierce, M.D., is the Scientific Director of the Immunopathology Lab in the Clinical Research Division at the Fred Hutchinson Cancer Research Center. Dr. Pierce is an Anatomic Pathologist with a strong academic and industry background in immuno-oncology. He was previously the Chief Scientific Officer of OncoSec. His research is focused on the mechanisms of tumor-induced immune tolerance and has longstanding expertise in the development of biomarkers to predict responses to immuno-oncology treatments. While at Merck, Dr. Pierce led a team focused on the development of tissue-based biomarkers for Merck’s anti-PD- 1 therapeutic antibody (pembrolizumab; KEYTRUDA®) and was the medical lead responsible for kicking-off the clinical trials of pembrolizumab in Merkel cell carcinoma and mycosis fungoides.

Robert Schreiber, Ph.D., is an Andrew M. Bursky and Jane M. Bursky Distinguished Professor of Pathology and Immunology, Professor of Molecular Microbiology, co-leader of the tumor immunology program at the Siteman Comprehensive Cancer Center and founding Director of the Center for Human Immunology and Immunotherapy Programs at The Washington University School of Medicine in St. Louis, Missouri. Schreiber is recognized globally as a pioneer in efforts to understand how the immune system may be useful in battling cancer.  His research interests include the molecular and cellular basis of cancer immunoediting (a process that he discovered whereby the immune system protects against cancer development and shapes tumor immunogenicity), the biology and signaling of cytokines with special emphasis on IFN-gamma and TNF, as well as the role of IFN-gamma in tumor immunity. He has served in leadership roles for many international organizations. His has achieved multiple honors, including the 2017 Balzan Prize for Immunological Approaches in Cancer Therapy, membership in the National Academy of Sciences (US), the American Academy of Arts and Sciences, the Cancer Research Institute’s Coley Award for Distinguished Research in Basic Tumor Immunology and the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

Daniel H. Sterman, M.D., is the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine in the Departments of Medicine and Cardiothoracic Surgery at the New York University School of Medicine, and Director of the Division of Pulmonary, Critical Care, and Sleep Medicine and Director of the Multidisciplinary Pulmonary Oncology Program at NYU Langone Health in New York City. He was previously lead clinical investigator in the multidisciplinary Thoracic Oncology Research Group at the Perelman School of Medicine at the University of Pennsylvania and the Principal Investigator of the Clinical Trials Project for the NCI.  Sterman’s research interests are related to the treatment of thoracic malignancies, specifically as they apply to the synergy of molecular medicine, tumor immunotherapy and novel technologies in Interventional Pulmonology.  Over the past 20 years, he has focused on the translation of laboratory discoveries from the bench to the bedside: conducting multiple human clinical trials of gene therapy and vaccine therapy for lung cancer, mesothelioma, and other pleural malignancies. More recently, as Director of the NYU PORT (Pulmonary Oncology Research Team), Dr. Sterman has expanded his research interests into assessment of the immune microenvironment of tumor-draining lymph nodes, as well as the development of local intra-tumoral and intra-nodal immunotherapies.